

2. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim [1, characterized in that] 4, wherein the benzofuran derivative [with antiarrhythmic activity] is dronedarone [or one of the pharmaceutically acceptable salts thereof] hydrochloride.
3. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim [1, characterized in that] 4, wherein the benzofuran derivative [with antiarrhythmic activity] is amiodarone [or one of the pharmaceutically acceptable salts thereof] hydrochloride.
4. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to 3, characterized in that] Claim 14 wherein the pharmaceutically acceptable salt is the hydrochloride.
5. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to 4, characterized in that] Claim 1 wherein the nonionic hydrophilic surfactant is [chosen] selected from the group consisting of poloxamers, polyethoxylated castor oils, ethoxylated polysorbates and polyethylene hydroxystearates.
6. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim 5[, characterized in that] wherein the nonionic hydrophilic surfactant is [chosen] selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the products Cremophor® RH 40 and Solutol® HS15.
7. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim [5 or 6, characterized in that] 15 wherein the nonionic hydrophilic surfactant is poloxamer 407.
8. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to 7, characterized in that] Claim 6 wherein the nonionic hydrophilic [agent] surfactant is present in a proportion of from 1% to 50% by weight of the active principle in base form.
9. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim 8, in tablet or gelatin capsule form, [characterized in that] wherein the nonionic hydrophilic surfactant is present in a proportion of from 1% to 20% by weight of the active principle in base form.
10. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim 9, in tablet or gelatin capsule form, [characterized in that] wherein the nonionic hydrophilic surfactant is present in a proportion of from 5% to 15% by weight of the active principle in base form.

11. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to 10, characterized in that it contains] Claim 8 containing from 50 to 500 mg of active principle.
12. (amended) [Pharmaceutical] A pharmaceutical composition according to Claim 11, in tablet or gelatin capsule form, [characterized in that it contains] containing from 200 to 400 mg of active principle.
13. (amended) [Pharmaceutical] A pharmaceutical composition according to [one of Claims 1 to] Claim 12, in tablet or gelatin capsule form, [characterized in that it contains] containing from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form.

Please add the following new claims:

14. A pharmaceutical composition according to Claim 1 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition according to Claim 6 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition according to Claim 7 wherein the benzofuran derivative is dronedarone hydrochloride.
17. A pharmaceutical composition according to Claim 10 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition according to Claim 17 wherein the nonionic hydrophilic surfactant is poloxamer 407.
19. A pharmaceutical composition according to Claim 18 wherein the benzofuran derivative is dronedarone hydrochloride.
20. A pharmaceutical composition according to Claim 13 wherein the active principle is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof and the nonionic hydrophilic surfactant is poloxamer 407.
21. A pharmaceutical composition according to claim 20 wherein the nonionic hydrophilic surfactant is poloxamer 407.